<html xmlns="http://www.w3.org/1999/xhtml"><body><table style="border: 1px solid black;"><caption /><tr><th style="border: 1px solid black;">Variable </th><th style="border: 1px solid black;">All patients </th><th style="border: 1px solid black;">Placebo group </th></tr><tr><td style="border: 1px solid black;">n treated</td><td style="border: 1px solid black;">86</td><td style="border: 1px solid black;">43</td></tr><tr><td style="border: 1px solid black;">Age (y)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">62.4 (8.7)</td><td style="border: 1px solid black;">62.7 (9.1)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">37–79</td><td style="border: 1px solid black;">43–79</td></tr><tr><td style="border: 1px solid black;">Sex, n (%)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Male</td><td style="border: 1px solid black;">57 (66)</td><td style="border: 1px solid black;">32 (74)</td></tr><tr><td style="border: 1px solid black;">Female</td><td style="border: 1px solid black;">29 (34)</td><td style="border: 1px solid black;">11 (26)</td></tr><tr><td style="border: 1px solid black;">Race, n (%)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">White</td><td style="border: 1px solid black;">83 (97)</td><td style="border: 1px solid black;">42 (98)</td></tr><tr><td style="border: 1px solid black;">Asian</td><td style="border: 1px solid black;">2 (2)</td><td style="border: 1px solid black;">1 (2)</td></tr><tr><td style="border: 1px solid black;">Other</td><td style="border: 1px solid black;">1 (1)</td><td style="border: 1px solid black;">0</td></tr><tr><td style="border: 1px solid black;">Country, n (%)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">US</td><td style="border: 1px solid black;">64 (74)</td><td style="border: 1px solid black;">32 (74)</td></tr><tr><td style="border: 1px solid black;">Italy</td><td style="border: 1px solid black;">10 (12)</td><td style="border: 1px solid black;">5 (12)</td></tr><tr><td style="border: 1px solid black;">Serbia</td><td style="border: 1px solid black;">8 (9)</td><td style="border: 1px solid black;">4 (9)</td></tr><tr><td style="border: 1px solid black;">Great Britain</td><td style="border: 1px solid black;">4 (5)</td><td style="border: 1px solid black;">2 (5)</td></tr><tr><td style="border: 1px solid black;">Modified H&amp;Y stage , n (%)^{a}</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">1.5</td><td style="border: 1px solid black;">3 (4)</td><td style="border: 1px solid black;">2 (5)</td></tr><tr><td style="border: 1px solid black;">2</td><td style="border: 1px solid black;">50 (58)</td><td style="border: 1px solid black;">24 (56)</td></tr><tr><td style="border: 1px solid black;">2.5</td><td style="border: 1px solid black;">20 (23)</td><td style="border: 1px solid black;">11 (26)</td></tr><tr><td style="border: 1px solid black;">3</td><td style="border: 1px solid black;">13 (15)</td><td style="border: 1px solid black;">6 (14)</td></tr><tr><td style="border: 1px solid black;">UPDRS Part III score, mean (SD)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">OFF state</td><td style="border: 1px solid black;">35.8 (12.0)</td><td style="border: 1px solid black;">36.2 (12.1)</td></tr><tr><td style="border: 1px solid black;">ON state</td><td style="border: 1px solid black;">17.5 (9.0)</td><td style="border: 1px solid black;">18.9 (9.8)</td></tr><tr><td style="border: 1px solid black;">Time since PD diagnosis (mon)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">113 (47)</td><td style="border: 1px solid black;">117 (48)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">38–255</td><td style="border: 1px solid black;">41–255</td></tr><tr><td style="border: 1px solid black;">Time since emergence of fluctuations (mon)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">51 (43)</td><td style="border: 1px solid black;">46 (40)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">0–254</td><td style="border: 1px solid black;">0–150</td></tr><tr><td style="border: 1px solid black;">OFF time (h/d)^{b}</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">5.7 (1.8)</td><td style="border: 1px solid black;">5.8 (1.5)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">2.6–10.3</td><td style="border: 1px solid black;">2.6–9.2</td></tr><tr><td style="border: 1px solid black;">Number of daily OFF episodes ^{c}</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">3.6 (1.1)</td><td style="border: 1px solid black;">3.7 (1.0)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">1.0–7.0</td><td style="border: 1px solid black;">1.7–6.0</td></tr><tr><td style="border: 1px solid black;">Duration of LD treatment (mon)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">93 (46)^{d}</td><td style="border: 1px solid black;">95 (48)^{e}</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">15–254^{d}</td><td style="border: 1px solid black;">15–243^{e}</td></tr><tr><td style="border: 1px solid black;">Number of daily LD doses</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">5.9 (1.9)</td><td style="border: 1px solid black;">6.1 (2.2)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">4–15</td><td style="border: 1px solid black;">4–15</td></tr><tr><td style="border: 1px solid black;">LD daily dosage (mg/d)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Mean (SD)</td><td style="border: 1px solid black;">770 (306)</td><td style="border: 1px solid black;">853 (315)</td></tr><tr><td style="border: 1px solid black;">Range</td><td style="border: 1px solid black;">250–1800</td><td style="border: 1px solid black;">400–1700</td></tr><tr><td style="border: 1px solid black;">Other oral PD medications, n (%)</td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td></tr><tr><td style="border: 1px solid black;">Dopamine agonists</td><td style="border: 1px solid black;">57 (66%)</td><td style="border: 1px solid black;">26 (61%)</td></tr><tr><td style="border: 1px solid black;">MAO-B inhibitors</td><td style="border: 1px solid black;">37 (43%)</td><td style="border: 1px solid black;">14 (33%)</td></tr><tr><td style="border: 1px solid black;">Adamantane derivatives</td><td style="border: 1px solid black;">29 (34%)</td><td style="border: 1px solid black;">13 (30%)</td></tr><tr><td style="border: 1px solid black;">COMT inhibitors</td><td style="border: 1px solid black;">9 (11%)</td><td style="border: 1px solid black;">5 (12%)</td></tr></table></body></html>